12,372 trials
Osteoarthritis, Knee
Primary: Mean Change From Baseline in WOMAC A (Pain) Dimension — -14.13; -17.16 score on a scale — p=0.0833
Glabellar Frown Lines
Primary: Percentage of Subjects Who Achieved ≥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales — 74.0; 1.0 percentage of responders
SARS-CoV-2 Infection
Primary: Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection (Part 1) — 4; 5; 9…
Lower Extremity Surgery · Bunion · Metatarsophalangeal Fushion
Primary: Magnitude of the Analgesic Effect (NRS Pain Intensity) (AUC) — 298.65; 358.10; 380.05 score on a scale*hours
Anemia · Dialysis-Dependent Chronic Kidney Disease
Primary: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) — 1.26; 1.58 Grams per deciliter (g/dL)
Ebola Virus Disease
Primary: Stages 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs) (Day 8) — 12; 51; 17; 14 Participants
Gaucher Disease
Primary: Number of Participants With Mobility Status Assessments at Study Baseline, Weeks 52, 104, 156 and 208 — 31; 0; 0; 0 Participants
Multiple Sclerosis · Spasticity, Muscle
Primary: Number of Participants With Adverse Events, Change in Vital Signs, Clinical Laboratory Test Results, 12-lead ECGs, USP Questionnaire, and C-SSRS Results — 276 Participants
Multiple Sclerosis · Spasticity, Muscle
Primary: Change From Baseline in Total Numeric-transformed Modified Ashworth Scale Score of the Most Affected Limb (TNmAS-MAL) — -1.7; -2.0; -1.4 units on a scale
Malaria, Falciparum
Primary: Polymerase Chain Reaction Corrected Efficacy Defined as Adequate Clinical and Parasitological Response (ACPR) by Study Arm — 146; 151 Participants — p=0.38
Tuberous Sclerosis Complex · Seizures
Primary: Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE) — 117; 75; 80; 60…
Hemophilia B
Primary: Total Number of Participants Who Developed Inhibitors Against Factor IX (FIX) — 0; 1 Participants
Post Operative Pain
Primary: Pain Level — 5.67; 4.09 score on a scale
Superficial Bladder Cancer
Primary: Number of Patients With a Complete Response Rate Based on Patients With Carcinoma in Situ (CIS), With or Without Concomitant High-grade Ta or T1 Papillary Disease. — 55…
Glabellar Frown Lines
Primary: Incidence of Treatment Emergent Adverse Events (TEAE) — 831; 267; 118 Participants